Metabolomics Pilot Study on Postoperative Intensive Care Acquired Muscle Weakness (MIRACLE-I Study)

What this Trial Is About

Researchers are investigating muscle weakness acquired in intensive care units (ICUAW) among surgical patients at high risk of ICU admission. This pilot study aims to examine changes in the blood metabolome and identify metabolic markers related to ICUAW. The study focuses on understanding metabolic and molecular factors associated with muscle weakness after critical illness and surgery. The study involves two groups: postoperative high-risk patients admitted to intensive care and elective surgery patients serving as controls. Blood and muscle samples will be collected at specific times to perform metabolic, histological, and molecular tests. These tests include metabolomics, muscle tissue analysis, and phosphoproteomics, centered around a median of 14 days after surgery or ICU admission. Participants will undergo blood and muscle sample collections along with muscle ultrasounds in the control group. The research team will monitor metabolic changes and muscle health over about two weeks. The main outcome is the metabolomics profile, with secondary outcomes including muscle tissue structure and protein phosphorylation. The study is conducted at a single center and sponsored by the Technical University of Munich, with a total participation period based on ICU stay and postoperative monitoring.

Metabolomics Study on Postoperative Intensive Care Acquired Muscle Weakness